Development of Diagnostic Imaging of Pancreatic Cancer using New PET Probe MePro

Not Applicable

• Conditions: pancreatic cancer

• Registration Number: JPRN-jRCTs031210472
• Lead Sponsor: Yamazaki Kana

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-07
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

1. Healthy male subjects aged 20 or older and under 65 at the time of informed consent
2. Subjects who provide written informed consent
3. Subjects with BMI of less than 25

Exclusion Criteria

1. Subjects who have severe or progressive complications
2. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent
3. Subjects who have past history of severe drug hypersensitivity
4. Subjects with drug or alcohol addiction
5. Subjects who smoke
6. Subjects who have received medication or used vitamins, herbal medicines or supplements within14 days prior to their visit
7. Subjects who are claustrophobic
8. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X-rays conducted as part of the annual medical check are excluded.
9. Subjects who are considered to be inappropriate to participate in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety of [11C]MePro in human subjects<br>Radiation dosimetry of [11C]MePro in human subjects

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of [11C]MePro